We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Persistence of xenogenized vaccine cells in vivo.
- Authors
Nicolas Graf; Christian Adam; Ralph Mocikat
- Abstract
Trioma cell vaccination is a potent new immunotherapeutic strategy for the treatment of B cell neoplasias. It is based on the specific redirection of tumor antigens against surface receptors on professional antigen-presenting cells (APC) that internalize antigens and present immunogenic peptides to T-lymphocytes. Tumor cells are converted to trioma cells by fusion with xenogeneic hybridomas expressing an anti-APC specificity. The trioma cell is a polyvalent vaccine that contains potentially all lymphoma-derived antigens. Apart from the expression of the APC-binding arm by the trioma cell, another requirement for successful tumor protection is the xenogeneic moiety of the trioma cells. We show that, despite their xenogenicity, trioma cells persist for extended periods in vaccinated animals. Trioma cells could be identified in spleens as long as about 12 weeks post vaccination. By using a suicide gene approach, trioma cells could partly be eliminated from immunized mice, whereby the antitumor effect was partly abrogated. We argue that not all trioma cells are immediately lysed in vivo and that the cell cycle of the remaining cells is arrested after having undergone few divisions. Trioma cells surviving in vivo may be instrumental for efficient induction of tumor immunity. © 2003 Wiley-Liss, Inc.
- Subjects
IMMUNOTHERAPY; CANCER cells; VACCINATION; B cell lymphoma; TUMOR antigens; ANTIGEN presenting cells; VACCINES; CELL cycle; TUMOR treatment
- Publication
International Journal of Cancer, 2003, Vol 105, Issue 2, p217
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.11065